


Sartorius Stedim acquires BioOutsource

22 April 2015 | News | By BioSpectrum Bureau

Sartorius Stedim acquires BioOutsource



Singapore: Sartorius Stedim Biotech (SSB), a global supplier for biopharmaceutical industries, acquired the Scottish company BioOutsource, a company engaged in providing contract testing services.

The company specializes in offering services for the fast growing biosimilar industry. Its assays are used in the early phases of drug characterization and comparability and for lot release testing of novel therapeutics. This acquisition will develop SSB's service offering throughout the drug development pathway.

Mr Reinhard Vogt, member, SSB's Board, commented, "By adding contract testing services, we will be able to support our biopharma clients even better in their drive to fast-track their new drug candidates through the development and clinical test phases and facilitate lot release testing in large scale manufacturing. The highly qualified team at BioOutsource will ideally complement our expertise, and we are looking forward to working with them."

"We are delighted to have found a strong partner with a broad customer base, international reach and a powerful brand. With Sartorius Stedim Biotech we will be able to scale our business to the next level and invest in new adjacent services, said Gerry MacKay, CEO of BioOutsource. "As a part of this group, we will have the opportunity to work with more international customers particularly in areas like the United States and Asia where there is significant investment in biosimilar development and manufacturing."